Beam Therapeutics Inc
BEAM20.010USD
+0.130+0.65%
Fechamento 07/03, 13:00（ET）Cotações atrasadas em 15 min
2.01BValor de mercado
PerdaP/L TTM
Mais detalhes de Beam Therapeutics Inc Empresa
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Informações da empresa
Código da empresaBEAM
Nome da EmpresaBeam Therapeutics Inc
Data de listagemFeb 06, 2020
Fundado em2017
CEOMr. John M. Evans
Número de funcionários483
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 06
Endereço238 Main Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone18573278775
Sitehttps://beamtx.com/
Código da empresaBEAM
Data de listagemFeb 06, 2020
Fundado em2017
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. John Maraganore, Ph.D.
Dr. John Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
7.47M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Farallon Capital Management, L.L.C.
9.87%
The Vanguard Group, Inc.
8.80%
ARK Investment Management LLC
8.43%
Fidelity Management & Research Company LLC
7.56%
BlackRock Institutional Trust Company, N.A.
6.72%
Other
58.61%
Investidores
Investidores
Proporção
Farallon Capital Management, L.L.C.
9.87%
The Vanguard Group, Inc.
8.80%
ARK Investment Management LLC
8.43%
Fidelity Management & Research Company LLC
7.56%
BlackRock Institutional Trust Company, N.A.
6.72%
Other
58.61%
Tipos de investidores
Investidores
Proporção
Investment Advisor
38.62%
Investment Advisor/Hedge Fund
29.38%
Hedge Fund
20.30%
Venture Capital
4.83%
Research Firm
2.23%
Sovereign Wealth Fund
1.82%
Individual Investor
1.28%
Bank and Trust
0.46%
Pension Fund
0.31%
Other
0.77%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
531
99.92M
99.37%
+13.13M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
2023Q1
583
68.81M
92.54%
-724.80K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Farallon Capital Management, L.L.C.
9.93M
9.87%
+1.69M
+20.50%
Mar 31, 2025
The Vanguard Group, Inc.
8.85M
8.8%
+1.24M
+16.36%
Mar 31, 2025
ARK Investment Management LLC
8.48M
8.43%
+1.41M
+19.98%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.60M
7.56%
+4.49M
+144.60%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.76M
6.72%
+838.01K
+14.15%
Mar 31, 2025
ARCH Venture Partners
4.54M
4.51%
--
--
Mar 31, 2025
Nikko Asset Management Co., Ltd.
4.27M
4.24%
+309.26K
+7.81%
Mar 31, 2025
State Street Global Advisors (US)
3.44M
3.42%
+362.74K
+11.79%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.94M
2.93%
+1.27M
+75.83%
Mar 31, 2025
Kynam Capital Management LP
2.52M
2.5%
+762.01K
+43.39%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Nome
Proporção
ARK Genomic Revolution ETF
3.47%
Global X Genomics & Biotechnology ETF
1.9%
WisdomTree BioRevolution Fund
1.65%
ARK Innovation ETF
1.6%
Virtus LifeSci Biotech Clinical Trials ETF
0.65%
Franklin Genomic Advancements ETF
0.61%
SPDR S&P Biotech ETF
0.47%
NYLI Healthy Hearts ETF
0.33%
Direxion Daily S&P Biotech Bull 3X Shares
0.28%
iShares Health Innovation Active ETF
0.17%
Ver Mais
ARK Genomic Revolution ETF
Proporção3.47%
Global X Genomics & Biotechnology ETF
Proporção1.9%
WisdomTree BioRevolution Fund
Proporção1.65%
ARK Innovation ETF
Proporção1.6%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.65%
Franklin Genomic Advancements ETF
Proporção0.61%
SPDR S&P Biotech ETF
Proporção0.47%
NYLI Healthy Hearts ETF
Proporção0.33%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.28%
iShares Health Innovation Active ETF
Proporção0.17%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
